Stimulation of dendritic cells with vaccine and vaccine–antibody complex and effect on immune response

Dendritic cell (DC) vaccines are a promising and potent therapeutic tool for chronic diseases, autoimmune diseases, and cancer because of the unique ability of DCs to stimulate T cells. The challenge of DC vaccines is to find an effective form for antigen presentation. | Turkish Journal of Biology Turk J Biol (2013) 37: 457-463 © TÜBİTAK doi: Research Article Stimulation of dendritic cells with vaccine and vaccine–antibody complex and effect on immune response 1,2, 3 1 1 2 1 İbrahim HATİPOĞLU *, İbrahim SÖĞÜT , Duygu ERCAN , Soner AKSU , Hülya SİVAS , Aynur BAŞALP 1 TÜBİTAK Marmara Research Center, Genetic Engineering and Biotechnology Institute, Gebze, Kocaeli, Turkey 2 Department of Biology, Faculty of Science, Anadolu University, Eskişehir, Turkey 3 Vocational School of Health Services, İstanbul Bilim University, İstanbul, Turkey Received: Accepted: Published Online: Printed: Abstract: Dendritic cell (DC) vaccines are a promising and potent therapeutic tool for chronic diseases, autoimmune diseases, and cancer because of the unique ability of DCs to stimulate T cells. The challenge of DC vaccines is to find an effective form for antigen presentation. Although pure antigens, antigen complexes, plasmids, and mRNA have been used in different studies, no proper application to overcome this problem has been found yet. In this study, we investigated the eligibility of a commercial hepatitis B virus (HBV) vaccine or a vaccine–monoclonal antibody complex for antigen loading of DCs for a therapeutic purpose. DCs were derived from the bone marrow of transgenic hepatitis B (HBV-tg) mice using a granulocyte macrophage-colony stimulating factor and interleukin-4, and then loaded with a commercial HBV vaccine (containing hepatitis B virus surface antigens and aluminum hydroxide adjuvant) or a vaccine–antibody complex. HBV-tg mice were immunized with the vaccine and vaccine–antibody loaded DCs. Optimum HBV vaccine concentration and loading time were determined by 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium (WST1) methods. Therapeutic effects of vaccine–antibody loaded DCs were determined by the .

Không thể tạo bản xem trước, hãy bấm tải xuống
TÀI LIỆU LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.